Niagen Bioscience Expands NAD+ IV Offerings to Cruise Ships via OneSpaWorld Partnership — Niagen Bioscience, Inc.

Event summary

Niagen Bioscience partners with OneSpaWorld to offer Niagen IV at over 80 Medi-Spa clinics onboard high-end cruise ships.
This marks Niagen Bioscience’s first cruise ship clinic partnership, expanding its Niagen Plus™ provider network.
Niagen IV is now available through Wells Pharma, a U.S. FDA-registered outsourcing facility.
The rollout is expected to expand across OneSpaWorld’s fleet, providing a scalable pathway for Niagen Plus to reach new consumers.

The big picture

Niagen Bioscience’s partnership with OneSpaWorld represents a strategic move to tap into the high-intent, on-vacation consumer market, aligning with broader trends in premium wellness experiences. This expansion strengthens Niagen Bioscience’s clinical channel footprint, supporting its strategy to scale Niagen IV and injections beyond the U.S. The collaboration introduces a new point of access for travelers seeking science-backed wellness solutions, potentially driving additional demand and market penetration.

What we're watching

Market Expansion: How the cruise ship channel will affect Niagen Bioscience’s revenue growth and consumer reach.
Regulatory Compliance: Whether Niagen Bioscience can maintain compliance with ship-specific Medi-Spa operations and applicable regulatory requirements.
Competitive Positioning: The pace at which Niagen Bioscience can differentiate its NAD+ IV offerings in the premium wellness market.